Selank dosage

Protocol

1. 1

   Reconstitute the vial

   Reconstitute the lyophilized vial with bacteriostatic water. The resulting concentration determines your syringe units per dose.

   Open tool →
2. 2

   Measure the dose

   Typical Selank dose is 0.4 mg (Intranasal: 250 to 500 mcg per nostril, 2 to 3 times daily (total 1.5 to 3 mg/day). Anecdotal SC use at 100 to 300 mcg.). Use a weight-based calculator for individual adjustments.

   Open tool →
3. 3

   Set the frequency

   Administer 2-3x daily (intranasal). Half-life of 0.5 hours anchors the dosing interval.

   Open tool →
4. 4

   Cycle if needed

   Russian protocols run 10 to 14 days. No Western-validated cycling data.

   Open tool →
5. 5

   Monitor for side effects

   Watch for: mild nasal irritation (intranasal); transient drowsiness (uncommon); mild headache. Stop or reduce dose if tolerability breaks down.

Why this dose

Modulates GABAergic, serotonergic, and dopaminergic signaling. Increases BDNF expression in hippocampal neurons in preclinical models. Modulates enkephalin levels and immune cytokine signaling via tuftsin-like activity.

The typical dose (0.4 mg) reflects Intranasal: 250 to 500 mcg per nostril, 2 to 3 times daily (total 1.5 to 3 mg/day). Anecdotal SC use at 100 to 300 mcg.. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

Selank is administered via the intranasal or subcutaneous routes. Subcutaneous injection into rotated abdominal sites is the standard self-administration approach for peptide protocols; rotate sites to limit local irritation. Use a fresh insulin syringe per dose. Intranasal delivery uses a metered spray; tilt the head slightly forward and breathe gently while spraying.

Onset of action runs around 15 minutes after administration. Peak effect lands near 1 hour post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: Plasma half-life ~30 minutes. Behavioral effects extend beyond plasma window in preclinical models, suggesting downstream signaling persistence.

Cycling and tolerance

Russian protocols run 10 to 14 days. No Western-validated cycling data.

The cycling rationale for receptor-active compounds is partly empirical and partly mechanistic: continuous high-dose stimulation can downregulate target receptors or accelerate negative-feedback loops on endogenous production. Built-in off-periods give the system time to resensitize before the next phase, which preserves the effective dose-response over a longer arc.

Effects to expect at typical dose

• Synthetic heptapeptide analog of tuftsin developed in Russia in the 1990s
• Approved in Russia for generalized anxiety disorder and asthenic conditions
• Russian RCTs report anxiolytic effects comparable to medazepam without sedation or dependence
• Modulates GABAergic and serotonergic signaling and BDNF expression in preclinical models
• Most commonly administered intranasally; subcutaneous use is anecdotal
• No Western-validated trials; not FDA approved; research-use-only outside Russia

Side effects and interactions

Common side effects

• mild nasal irritation (intranasal)
• transient drowsiness (uncommon)
• mild headache

Notable interactions

• benzodiazepines (moderate): additive anxiolytic effect; potential for over-sedation when stacked
• SSRIs (minor): no documented adverse interaction; co-administration described in Russian protocols

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Selank profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

unknown

DEA / Rx

Not FDA approved; not scheduled; research-chemical status outside Russia

Pregnancy

Not recommended; insufficient data

Legal status

Approved as a prescription anxiolytic in Russia; not FDA approved; research-use-only grey market in most other jurisdictions

Do not use if

• pregnancy
• lactation
• severe psychiatric disorder (insufficient data)

Related research